» Articles » PMID: 33665229

Molecular Subtyping and Functional Validation of TTK, TPX2, UBE2C, and LRP8 in Sensitivity of TNBC to Paclitaxel

Overview
Publisher Cell Press
Date 2021 Mar 5
PMID 33665229
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Triple-negative breast cancer (TNBC) patients exhibit variable responses to chemotherapy, suggesting an underlying molecular heterogeneity. In the current study, we analyzed publicly available transcriptome data from 360 TNBC and 88 normal breast tissues, which revealed activation of nucleosome and cell cycle as the hallmarks of TNBC. Mechanistic network analysis identified activation of FOXM1 and ERBB2, and suppression of TP53 and NURP1 networks in TNBC. Employing Iterative Clustering and Guide-gene Selection (ICGS), Uniform Manifold Approximation and Projection (UMAP), and dimensionality reduction analyses, we classified TNBC into seven molecular subtypes, each exhibiting a unique molecular signature, including immune infiltration (CD19, CD8, and macrophages) and mesenchymal signature, which correlated with variable disease outcomes in a larger cohort (1,070) of BC. Mechanistically, depletion of , , , , , , , and led to substantial inhibition of colony formation of TNBC models, which was further enhanced in the presence of paclitaxel. Our data provide novel insights into the molecular heterogeneity of TNBC and identified , , , and as main drivers of TNBC tumorigenesis.

Citing Articles

Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination.

Zanini E, Forster-Gross N, Bachmann F, Brungger A, McSheehy P, Litherland K Front Oncol. 2024; 14:1447807.

PMID: 39184047 PMC: 11341980. DOI: 10.3389/fonc.2024.1447807.


New insight into the CNC-bZIP member, NFE2L3, in human diseases.

Xiong G, Li J, Yao F, Yang F, Xiang Y Front Cell Dev Biol. 2024; 12:1430486.

PMID: 39149514 PMC: 11325725. DOI: 10.3389/fcell.2024.1430486.


A Novel Methylation-based Model for Prognostic Prediction in Lung Adenocarcinoma.

Li M, Deng X, Zhou D, Liu X, Dai J, Liu Q Curr Genomics. 2024; 25(1):26-40.

PMID: 38544827 PMC: 10964088. DOI: 10.2174/0113892029277397231228062412.


Seize the engine: Emerging cell cycle targets in breast cancer.

Fuentes-Antras J, Bedard P, Cescon D Clin Transl Med. 2024; 14(1):e1544.

PMID: 38264947 PMC: 10807317. DOI: 10.1002/ctm2.1544.


Role of UBE2C in Brain Cancer Invasion and Dissemination.

Domentean S, Paisana E, Cascao R, Faria C Int J Mol Sci. 2023; 24(21).

PMID: 37958776 PMC: 10650073. DOI: 10.3390/ijms242115792.


References
1.
Garcia-Teijido P, Cabal M, Pelaez Fernandez I, Perez Y . Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. Clin Med Insights Oncol. 2016; 10(Suppl 1):31-9. PMC: 4822722. DOI: 10.4137/CMO.S34540. View

2.
Jiang Y, Ma D, Suo C, Shi J, Xue M, Hu X . Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell. 2019; 35(3):428-440.e5. DOI: 10.1016/j.ccell.2019.02.001. View

3.
Denkert C, Loibl S, Noske A, Roller M, Muller B, Komor M . Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2009; 28(1):105-13. DOI: 10.1200/JCO.2009.23.7370. View

4.
Muranen T, Blomqvist C, Dork T, Jakubowska A, Heikkila P, Fagerholm R . Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium. Breast Cancer Res. 2016; 18(1):98. PMC: 5048645. DOI: 10.1186/s13058-016-0758-5. View

5.
Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T . Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing. Cell. 2018; 173(4):879-893.e13. PMC: 6132060. DOI: 10.1016/j.cell.2018.03.041. View